Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson's disease (PD). Background: Despite decades of intensive research, to date,…Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease
Objective: Non-dopaminergic protein drug targets are of high interest to develop adjuvant treatments for currently insufficiently addressed symptoms of PD. RGS4, a regulator of G-protein…Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?
Objective: To assess the frequency of neuropathy and its neurophysiological characteristics in orally and levodopa/carbidopa intestinal gel (LCIG) treated patients with advanced idiopathic Parkinson´s disease…Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis
Objective: Vitamin D is an important factor responsible for many physiologic functions. Vitamin D deficiency is associated with increased risk of neurodegenerative disease. Background: The…Switching double-blind opicapone, entacapone or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I
Objective: Evaluate the efficacy of opicapone (OPC) in Parkinson's disease (PD) patients with motor fluctuations enrolled in the 1-year extension of study BIPARK I. Background:…Minimizing levodopa titration period for Parkinson’s disease (PD)
Objective: Develop an optimization algorithm that individualizes the pharmacokinetics-pharmacodynamics (PKPD) infusion models of levodopa, to improve the efficacy of dose titration and reduce the number…Parkinson patient reported outcomes of voice and communication pre, post and 6 months following LSVT LOUD® and LSVT ARTIC
Objective: To evaluate the functional impact of LSVT LOUD and LSVT ARTIC on voice and communication in individuals with Parkinson's disease (PD) immediately post and…STN-DBS in Parkinson’s disease with early motor complications – A 10 year follow-up
Objective: To investigate long-term outcome of subthalamic stimulation (STN-DBS).in Parkinson's disease (PD) patients with early motor complications. Background: STN-DBS improves motor complications and quality of…Drug safety in the pharmacotherapy of Parkinson’s disease
Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.